Abbott is in a sustained downtrend, with the stock down 29.7% over the past year compared to the S&P 500's gain of 20.6%. The current price of $93.93 sits at 68.3% of its 52-week range ($81.97 low to $137.49 high), indicating the stock is closer to its lows than highs. This positioning suggests the market is pricing in significant negative sentiment, but also raises the possibility of a value opportunity if fundamentals stabilize. The 1-year relative strength of -50.3% underscores severe underperformance versus the market.

Revenue has grown steadily, with Q4 2025 revenue of $11.46 billion up 4.4% year-over-year, driven by Medical Devices ($5.68 billion) and Nutritional Products ($1.94 billion). However, growth has decelerated from the 10.4% YoY growth seen in Q2 2022, and the company's 2026 guidance cut signals further slowing. The Established Pharmaceuticals segment contributed $1.38 billion, but overall revenue growth is moderating as pandemic-related diagnostics demand fades. Net income for Q4 2025 was $1.78 billion, with a net margin of 15.5%, while gross margin improved to 57.0% from 51.0% a year earlier. Operating margin of 19.6% is healthy and stable, reflecting cost discipline despite revenue mix shifts. The company is solidly profitable with consistent earnings. Abbott generated $3.32 billion in operating cash flow and $2.63 billion in free cash flow in Q4 2025, with free cash flow per share of $1.50. The debt-to-equity ratio is low at 0.29, and the current ratio of 1.58 indicates ample liquidity. ROE stands at 12.5%, demonstrating efficient capital use, and the company has $8.52 billion in cash, providing a strong buffer for investments and dividends.